Skip to content

Study · Not a test of the peptide alone · 1998

7 results

Measurement of an analog of insulin-like growth factor-I in blood plasma using a novel enzyme-linked immunosorbent assay.

Gajanandana O, Irvine K, Grant PA, Francis GL, Knowles SE, Wrin J, Wallace JC, Owens PC

The Journal of endocrinology1 Mar 1998Cited by 2 (Europe PMC)

PMID9582496 (opens in a new tab)DOI10.1677/joe.0.1560407 (opens in a new tab)PepBankPUB-09582496
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneOther designOther

    A noncompetitive ELISA detected as little as 50 pg LR3IGF-I in 100 microliters.

    In plain wordsA new lab test can detect very small amounts of LR3IGF-I, as little as 50 pg.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA detection limit
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    detection limit
    50 pg
    LR3IGF-I in 100 microliters

    Source sentences

    Summary
    The ELISA system was able to detect as little as 50 pg LR3IGF-I in 100 microliters
    1 context sentence
    Summary · context
    We have developed a sensitive noncompetitive nonisotopic assay of LR3IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02LabNot a test of IGF-1 LR3 aloneOther designOther

    The ELISA gave less than 0.01% activity with native IGF-I and IGF-II.

    In plain wordsThe lab test barely responds to natural IGF-I and IGF-II, so it picks out LR3IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA cross-reactivity with native IGFs
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    activity of native IGFs-I and -II
    < 0.01%
    ELISA

    Source sentences

    Summary
    the native peptides IGFs-I and -II have less than 0.01% activity.
    1 context sentence
    Summary · context
    We have developed a sensitive noncompetitive nonisotopic assay of LR3IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  3. 03LabNot a test of IGF-1 LR3 aloneOther designOther

    Plasma from treated animals could be diluted 33.3-fold before assay, and at that dilution plasma had no significant effect on the assay.

    In plain wordsPlasma from treated animals could be diluted 33.3-fold without affecting the lab test.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA plasma interference
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    plasma dilution without assay interference
    33.3 fold
    ELISA

    Source sentences

    Summary
    Blood plasma from animals treated with pharmacologically active doses of this growth factor analog could be diluted 33.3-fold before assay, at which concentrations plasma had no significant effect on the assay.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  4. 04LabNot a test of IGF-1 LR3 aloneOther designOther

    The ELISA response to LR3IGF-I was unaffected by the presence of IGF-binding proteins.

    In plain wordsThe lab test for LR3IGF-I was not affected by IGF-binding proteins.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA response with IGF-binding proteins
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    The ELISA response to LR3IGF-I was unaffected by the presence of IGF-binding proteins.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  5. 05LabNot a test of IGF-1 LR3 aloneOther designOther

    The ELISA had intra-assay and interassay coefficients of variation of 2.8 and 7.3%.

    In plain wordsThe lab test gave repeatable results, with variation of 2.8% within runs and 7.3% between runs.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA precision
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    intra-assay coefficient of variation
    2.8%
    ELISA
    interassay coefficient of variation
    7.3%
    ELISA

    Source sentences

    Summary
    The intra-assay and interassay coefficients of variation are 2.8 and 7.3% respectively.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  6. 06LabNot a test of IGF-1 LR3 aloneOther designOther

    Recovery of LR3IGF-I added to blood plasma was approximately 90%.

    In plain wordsAbout 90% of LR3IGF-I added to blood plasma was recovered by the lab test.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA recovery from plasma
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    recovery
    ≈ 90%
    LR3IGF-I added to blood plasma

    Source sentences

    Summary
    Recovery of LR3IGF-I added to blood plasma was approximately 90%.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  7. 07LabNot a test of IGF-1 LR3 aloneOther designOther

    In plasma of cows treated with LR3IGF-I, ELISA results correlated positively with results from the established RIA.

    In plain wordsIn plasma from treated cows, the new lab test agreed with an older test, with a positive correlation.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableELISA agreement with RIA in cow plasma
    Study

    cown: not reported in source

    cow plasma
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    There was a positive correlation between results obtained by the two assays.
    1 context sentence
    Summary · context
    The ELISA was used to measure LR3IGF-I concentrations in plasma of cows treated with a pharmacologically active dose of this peptide

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.